2445 Technology Forest Boulevard
11th Floor
The Woodlands, TX 77381
United States
281 863 3000
https://www.lexpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Lonnel Coats | CEO & Director | 1.22M | N/A | 1965 |
Mr. Jeffrey L. Wade J.D. | President & CFO | 788.65k | N/A | 1965 |
Mr. Brian T. Crum | Senior VP, General Counsel & Secretary | 609.1k | N/A | 1974 |
Dr. Kenneth B. Kassler-Taub M.D. | Senior Vice President of Regulatory Affairs & Quality Assurance | 588.7k | N/A | 1957 |
Dr. Craig B. Granowitz M.D., Ph.D. | Senior VP & Chief Medical Officer | 671.14k | N/A | 1966 |
Dr. Robert J. Lefkowitz M.D. | Consultant & Independent Director | 50k | N/A | 1944 |
Ms. Kristen L. Alexander | Vice President of Finance & Accounting | N/A | N/A | 1968 |
Ms. Lisa M. DeFrancesco | Head of Investor Relations & Corporate Strategy | N/A | N/A | 1980 |
Mr. Dixon Terry | Vice President of Compliance | N/A | N/A | N/A |
Chas Schultz | Executive Director of Corporate Communications & Patient Advocacy | N/A | N/A | N/A |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 10. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 7; Compensation: 10.